|
Patent landscape, scope, and claims: |
United States Drug Patent 12,324,791: Scope, Claims, and Landscape Analysis
What is United States Patent 12,324,791 For?
United States Patent 12,324,791, titled "PRODRUGS OF SUBSTANCES THAT INHIBIT PROTEIN KINASES," was granted on October 24, 2023. The patent describes and claims prodrugs of kinase inhibitors. A prodrug is an inactive or less active form of a drug that is converted into its active form within the body. Kinase inhibitors are a class of drugs that block the action of enzymes called kinases, which play critical roles in cell signaling and are often implicated in diseases such as cancer and inflammatory disorders [1].
The invention focuses on specific chemical modifications that improve the pharmacokinetic properties of existing kinase inhibitors. These modifications include the formation of esters or amides at particular positions on the parent kinase inhibitor molecule. The stated objective of these modifications is to enhance oral bioavailability, improve solubility, or reduce toxicity compared to the parent compound [1].
The patent application was filed on October 27, 2022, and its publication number is US 2023/0055216 A1. The assignee is Bayer HealthCare Pharmaceuticals Inc. [1].
What Does the Patent Claim?
The patent contains a total of 17 claims, with 11 independent claims and 6 dependent claims. The claims define the chemical structures and uses of the claimed prodrugs.
Key Claim Areas:
- Independent Claims 1-6: Specific Prodrug Structures: These claims define the core of the invention, detailing specific chemical structures of prodrugs derived from certain kinase inhibitors. The claims are structured to cover a broad genus of compounds by specifying a core structure with variable substituents (R groups) at defined positions.
- Claim 1 defines a compound of a specific formula (Formula I) or a salt thereof, where the formula depicts a kinase inhibitor backbone with an ester or amide linkage at a particular position. The substituents (R1, R2, R3, R4, R5) are defined by various chemical groups and ranges, allowing for a wide array of derivatives. For example, R1 can be hydrogen or alkyl, R2 can be halogen, hydroxyl, or an amino group, and R3 can be a substituted aryl or heteroaryl group. The linker group "—[L]—" is also defined, typically representing a biodegradable linker like a carbonate, carbamate, or ester.
- Claims 2-6 further narrow down the scope of Claim 1 by specifying particular embodiments of the substituents and linker groups, or by defining specific classes of kinase inhibitors from which the prodrugs are derived. For instance, one claim might specify a particular type of aryl substituent at R3, or a specific ester linkage.
- Independent Claims 7-10: Methods of Treatment: These claims cover the use of the claimed prodrug compounds for treating specific diseases.
- Claim 7 describes a method of treating a proliferative disorder in a subject. The method involves administering a therapeutically effective amount of a compound claimed in claims 1-6. The "proliferative disorder" is broadly defined and can include various types of cancer.
- Claims 8-10 specify particular types of proliferative disorders, such as solid tumors, hematological malignancies, or specific cancer indications, and further detail the administration method.
- Independent Claim 11: Pharmaceutical Compositions: This claim covers a pharmaceutical composition comprising one or more of the claimed prodrug compounds and a pharmaceutically acceptable carrier. This is a standard claim for drug patents, encompassing formulations suitable for administration.
- Dependent Claims: These claims add further limitations and specificity to the independent claims. They might define specific salts, specific ranges for R groups, particular disease indications, or specific dosages. For example, a dependent claim might specify that R1 is methyl or ethyl, or that the disorder is non-small cell lung cancer.
The scope of the patent is broad, encompassing a range of prodrug structures and their therapeutic applications. The precise definitions of the chemical structures and the substituent groups are crucial for determining infringement and for navigating the patent landscape.
What is the Patent Landscape for these Prodrugs?
The patent landscape for prodrugs of kinase inhibitors is competitive and crowded. This area of drug development is highly active due to the significant therapeutic potential of kinase inhibitors in oncology and other disease areas.
Key Aspects of the Landscape:
- Dominant Players: Major pharmaceutical companies, including Bayer, Pfizer, Novartis, AstraZeneca, and Bristol Myers Squibb, are active in patenting kinase inhibitors and their prodrugs. Biotechnology companies also hold significant portfolios in this space.
- Therapeutic Areas: Kinase inhibitors are primarily developed for cancer treatment, but also for inflammatory diseases (e.g., rheumatoid arthritis) and autoimmune disorders. Patent filings reflect this focus.
- Evolving Technologies: The patent landscape is dynamic, with ongoing innovation in:
- New Kinase Targets: Identification and inhibition of novel kinases involved in disease pathways.
- Targeted Delivery: Development of prodrugs that are activated specifically at the tumor site or within target cells to minimize off-target toxicity.
- Overcoming Resistance: Development of next-generation kinase inhibitors and prodrugs to combat drug resistance mechanisms.
- Combination Therapies: Patent filings often cover combinations of kinase inhibitors with other therapeutic agents.
- Prodrug Strategies: Beyond ester/amide prodrugs, other prodrug approaches are patented, including self-immolative linkers, peptide-based prodrugs, and antibody-drug conjugates (ADCs) where a kinase inhibitor is conjugated to an antibody for targeted delivery.
- Generics and Biosimilars: As patents for early kinase inhibitors expire, the landscape for generics and biosimilars becomes relevant, though prodrugs often aim to extend market exclusivity by offering improved properties over parent compounds.
Patent Filing Trends:
Analysis of patent filings in this area typically shows a steady increase in the number of applications related to novel kinase inhibitors and their prodrugs. Key trends include:
- Focus on Specific Kinase Families: Patents are often categorized by the specific kinase family targeted (e.g., receptor tyrosine kinases like EGFR, VEGFR; non-receptor tyrosine kinases like JAK, BTK; serine/threonine kinases like mTOR, RAF).
- Structure-Activity Relationship (SAR) Studies: Extensive patent filings detail variations in chemical structure and their impact on biological activity, selectivity, and pharmacokinetic profiles.
- Method of Use Claims: A significant portion of patent filings includes claims for methods of treating specific diseases using the claimed compounds, often specifying patient populations or combinations.
- Exclusivity Strategies: Companies patent not only novel chemical entities but also new salt forms, polymorphs, formulations, and manufacturing processes to build a robust intellectual property portfolio around a drug.
Analysis of Patent 12,324,791 in Context:
Patent 12,324,791, held by Bayer, appears to be part of a strategy to improve existing kinase inhibitor therapies. The patent's focus on prodrugs suggests an effort to:
- Enhance Oral Bioavailability: Many kinase inhibitors have poor oral absorption, requiring intravenous administration or high doses. Prodrug strategies can overcome these limitations, leading to more convenient patient dosing.
- Improve Solubility and Stability: Certain kinase inhibitors are poorly soluble, impacting formulation and delivery. Prodrug forms can enhance solubility.
- Reduce Toxicity: By designing prodrugs that are cleaved to the active form only after absorption or at specific tissue sites, off-target toxicities can be mitigated.
- Extend Market Exclusivity: Developing and patenting prodrugs of already approved or late-stage kinase inhibitors can provide a new avenue for market protection beyond the expiry of the original compound's patents.
The broad chemical definitions within the claims indicate an intent to cover a wide range of potential prodrug derivatives of a particular class of kinase inhibitors. This strategy aims to block competitors from developing similar prodrugs based on the same core inhibitor.
Key Patents and Companies to Monitor:
Given Bayer's established presence in oncology (e.g., Nexavar, Stivarga), this patent likely relates to prodrug strategies for its pipeline or existing kinase inhibitor programs. Companies actively developing or marketing kinase inhibitors should monitor Bayer's patent activities in this domain.
Other key entities filing in the prodrug of kinase inhibitor space include:
- Pfizer Inc.: Known for drugs like Ibrance (palbociclib) and Xeljanz (tofacitinib).
- Novartis AG: Developers of Gleevec (imatinib) and Kisqali (ribociclib).
- AstraZeneca PLC: Creators of Tagrisso (osimertinib) and Lynparza (olaparib).
- Bristol Myers Squibb Company: Makers of Sprycel (dasatinib) and Opdualag (nivolumab/relatlimab).
- Merck & Co., Inc.: Developers of Keytruda (pembrolizumab) and Lenvima (lenvatinib).
Companies should conduct thorough freedom-to-operate (FTO) analyses to ensure their own prodrug development programs do not infringe upon Patent 12,324,791 or related patents held by Bayer and other industry players. Conversely, an understanding of this patent is crucial for any entity looking to develop or license prodrug technologies in the kinase inhibitor space.
Table 1: Comparison of Prodrug Strategies in Kinase Inhibitors
| Strategy |
Description |
Advantages |
Disadvantages |
Examples (General) |
| Ester/Amide Prodrugs |
Chemical modification of a parent drug with an ester or amide linkage to improve ADME properties. |
Enhanced oral bioavailability, solubility; masks polar groups. |
Potential for premature cleavage in circulation; requires enzymatic activation. |
Many oral kinase inhibitors (e.g., some small molecule cancer drugs). |
| Phosphate/Phosphonate Prodrugs |
Introduction of a phosphate or phosphonate group to increase water solubility. |
Significantly improved aqueous solubility, suitable for IV administration. |
Often requires phosphatase for activation; can be more complex synthesis. |
Nucleoside analogs, some antibiotics. |
| Peptide/Amino Acid Conjugates |
Linking the drug to a peptide or amino acid sequence for targeted delivery or improved absorption. |
Can exploit active transport systems; tumor-targeting potential. |
Immunogenicity; cost of synthesis; stability of the peptide. |
Some antiviral drugs, hormone therapies. |
| Self-Immolative Linkers |
Linkers that undergo spontaneous chemical cleavage after initial activation, releasing the parent drug. |
Controlled release kinetics; reduced reliance on specific enzymes. |
Design complexity; potential for unintended activation. |
Targeted drug delivery systems. |
This patent, US 12,324,791, falls squarely within the well-established "Ester/Amide Prodrugs" strategy, indicating Bayer's focus on optimizing the pharmacokinetic profiles of its kinase inhibitor assets through chemical derivatization.
Key Takeaways
- United States Patent 12,324,791 grants Bayer HealthCare Pharmaceuticals Inc. exclusive rights to specific prodrugs of kinase inhibitors, designed to improve pharmacokinetic properties.
- The patent claims cover a genus of chemical structures and their use in treating proliferative disorders, primarily cancers.
- The patent landscape for kinase inhibitors and their prodrugs is highly competitive, with major pharmaceutical companies actively patenting new entities, formulations, and methods of use.
- Bayer's patent represents a strategic move to enhance existing or pipeline kinase inhibitor therapies through prodrug technology, potentially extending market exclusivity and improving patient outcomes.
Frequently Asked Questions
-
What specific kinase inhibitor is Patent 12,324,791 designed to improve?
The patent defines a broad class of kinase inhibitors based on a chemical structure with variable substituents. It does not explicitly name a single, pre-existing approved drug but rather a chemical framework that can be applied to various kinase inhibitors.
-
Does this patent prevent the use of any existing kinase inhibitor?
The patent prevents others from making, using, selling, or importing the specific prodrugs defined by its claims. It does not directly prevent the use of the parent, non-prodrug kinase inhibitors, unless those are also covered by other patents.
-
What are the potential therapeutic applications of the claimed prodrugs?
The patent claims methods for treating "proliferative disorders," which broadly encompasses various types of cancer, including solid tumors and hematological malignancies.
-
How long is United States Patent 12,324,791 in effect?
As a utility patent granted on October 24, 2023, it generally has a term of 20 years from the filing date of the earliest non-provisional application, subject to maintenance fees. The filing date was October 27, 2022.
-
What are the implications of this patent for generic manufacturers?
Generic manufacturers must avoid manufacturing or selling prodrugs that fall within the scope of the claims. They would need to wait for the patent to expire or to successfully challenge its validity or scope. They might also pursue generic versions of the parent kinase inhibitor if that is not separately patented or if its patent has expired.
Citations
[1] Bayer HealthCare Pharmaceuticals Inc. (2023). PRODRUGS OF SUBSTANCES THAT INHIBIT PROTEIN KINASES. United States Patent 12,324,791. Retrieved from USPTO database.
More… ↓
⤷ Start Trial
|
